American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 51-58 , January 2009

Advanced Glycation End Products and Their Circulating Receptors and Level of Kidney Function in Older Community-Dwelling Women

  • Richard D. Semba, MD, MPH

      Affiliations

    • Johns Hopkins Medical Institutions, Bethesda, MD
    • Corresponding Author InformationAddress correspondence to Richard Semba, MD, MPH, 550 N Broadway, Ste 700, Baltimore, MD 21205
    • ,
  • Luigi Ferrucci, MD, PhD

      Affiliations

    • Longitudinal Studies Section, Clinical Research Branch, National Institute on Aging, Bethesda, MD
    • ,
  • Jeffrey C. Fink, MD, MS

      Affiliations

    • Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Bethesda, MD
    • ,
  • Kai Sun, MS

      Affiliations

    • Johns Hopkins Medical Institutions, Bethesda, MD
    • ,
  • Justine Beck, BS

      Affiliations

    • Johns Hopkins Medical Institutions, Bethesda, MD
    • ,
  • Mansi Dalal, BS

      Affiliations

    • Johns Hopkins Medical Institutions, Bethesda, MD
    • ,
  • Jack M. Guralnik, MD, PhD

      Affiliations

    • Epidemiology and Demography Section, Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Bethesda, MD
    • ,
  • Linda P. Fried, MD, MPH

      Affiliations

    • Johns Hopkins Medical Institutions, Bethesda, MD

Received 18 February 2008 ,Accepted 18 June 2008.

References 

  1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–2047
  2. Schiffrin EL, Lipman ML, Mann JFE. Chronic kidney disease: Effects on the cardiovascular system. Circulation. 2007;116:85–97
  3. Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diabetes Rep. 2007;7:235–241
  4. Basta G, Schmidt AM, de Caterina R. Advanced glycation end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63:582–592
  5. Bohlender JM, Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Renal Physiol. 2005;289:F645–F659
  6. Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product Nε-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457–468
  7. Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287–1291
  8. Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94:6474–6479
  9. Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A. 2002;99:15596–15601
  10. Uribarri J, Peppa M, Cai W, et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis. 2003;42:532–538
  11. Negrean M, Stirban A, Stratmann B, et al. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr. 2007;85:1236–1243
  12. Kass DA, Shapiro EP, Kawaguchi M, et al. Improved arterial compliance by a novel advanced glycation end-product crosslink breaker. Circulation. 2001;104:1464–1470
  13. Little WC, Zile MR, Kitzman DW, et al. The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail. 2005;11:191–195
  14. Bolton WK, Cattran DC, Williams ME, et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol. 2004;24:32–40
  15. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol. 2007;27:605–614
  16. Degenhardt TP, Alderson NL, Arrington DD, et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 2002;61:939–950
  17. Forbes JM, Thallas V, Thomas MC, et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J. 2003;17:1762–1764
  18. Susic D, Varagic J, Ahn J, Frohlich ED. Cardiovascular and renal effects of a collagen cross-link breaker (ALT 711) in adult and aged spontaneously hypertensive rats. Am J Hypertens. 2004;17:328–333
  19. Basta G. Receptor for advanced glycation endproducts and atherosclerosis: From basic mechanisms to clinical implications. Atherosclerosis. 2008;196:9–21
  20. Schmidt AM, Vianna M, Gerlach M, et al. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987–14997
  21. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998–15004
  22. Yonekura H, Yamamoto Y, Sakurai S, et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J. 2003;370:1097–1109
  23. Hudson BI, Harja E, Moser B, Schmidt AM. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: The next C-reactive protein?. Arterioscler Thromb Vasc Biol. 2005;24:879–882
  24. Wautier JL, Zoukourian C, Chappey O, et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest. 1996;97:238–243
  25. Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: From disease marker to potential therapeutic target. Curr Med Chem. 2006;13:1971–1978
  26. Challier M, Jacqueminet S, Benabdesselam O, Grimaldi A, Beaudeux JL. Increased serum concentrations of soluble receptor for advanced glycation endproducts in patients with type 2 diabetes. Clin Chem. 2005;51:1749–1750
  27. Tan KCB, Shiu SWM, Chow WS, Leng L, Bucala R, Betteridge DJ. Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia. 2006;49:2756–2762
  28. Sakurai S, Yamamoto Y, Tamei H, et al. Development of an ELISA for esRAGE and its application to type 1 diabetic patients. Diabetes Res Clin Pract. 2006;73:158–165
  29. Kalousová M, Hodková M, Kazderová M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006;47:406–411
  30. Guralnik JM, Fried LP, Simonsick EM, Kasper D, Lafferty ME. The Women's Health and Aging Study: Health and Social Characteristics of Older Women with Disability. NIH Publication No. 95-4009. Bethesda, MD: National Institute on Aging; 1995;
  31. Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198
  32. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry. 1995;34:10872–10878
  33. Boehm BO, Schilling S, Rosinger S, et al. Elevated serum levels of Nϵ-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia. 2004;47:1376–1379
  34. Zhang X, Frischmann M, Kientsch-Engel R, et al. Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients. Clin Chem Lab Med. 2005;43:503–511
  35. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001;9(suppl 4):S228–S233
  36. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med. 1999;130:461–470
  37. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end-products in patients with diabetic nephropathy. N Engl J Med. 1991;325:836–842
  38. Mostafa AA, Randell EW, Vasdev SC, et al. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. Mol Cell Biochem. 2007;302:35–42
  39. Miyata T, Ueda Y, Shinzato T, et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol. 1996;7:1198–1206
  40. Suliman ME, Heimbürger O, Bárány P, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol. 2003;14:1614-1422
  41. Hou FF, Ren H, Owen WF, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol. 2004;15:1889–1896
  42. Linden E, Cai W, He JC, et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol. 2008;3:691–698
  43. Gugliucci A, Bendayan M. Renal fate of circulating advanced glycated end products (AGE): Evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia. 1996;39:149–160
  44. Miyata T, Ueda Y, Horie K, et al. Renal catabolism of AGEs: The fate of pentosidine. Kidney Int. 1998;53:416–422
  45. Schinzel R, Münch G, Heidland A, Sebekova K. Advanced glycation end products in end-stage renal disease and their removal. Nephron. 2001;87:295–303
  46. Busch M, Franke S, Wolf G, et al. The advanced glycation end product Nε-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension. Am J Kidney Dis. 2006;48:571–579
  47. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91:11704–11708
  48. Yang CW, Vlassara H, Peten EP, et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A. 1994;91:9436–9440
  49. Bostom A. Homocysteine: “Expensive creatinine” or important modifiable risk factor for arteriosclerotic outcomes in renal transplant recipients?. J Am Soc Nephrol. 2000;11:149–151
  50. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA. 2007;298:1212–1214
  51. Levey AS, Coresh J, Greene T, et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007;53:766–772
  52. Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728–731
  53. Semba RD, Ferrucci L, Sun K, et al: Advanced glycation end products and their circulating receptors predict cardiovascular disease mortality in older community-dwelling women. Aging Clin Exp Res (in press)
  54. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol. 2005;16:2363–2372

 Originally published online as doi:10.1053/j.ajkd.2008.06.018 on September 16, 2008.

PII: S0272-6386(08)01113-X

doi: 10.1053/j.ajkd.2008.06.018

American Journal of Kidney Diseases
Volume 53, Issue 1 , Pages 51-58 , January 2009

Article Tools